Compare ATLO & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATLO | ADAG |
|---|---|---|
| Founded | 1903 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.2M | 254.4M |
| IPO Year | 2001 | 2020 |
| Metric | ATLO | ADAG |
|---|---|---|
| Price | $28.51 | $3.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 62.5K | ★ 312.2K |
| Earning Date | 04-24-2026 | 04-01-2026 |
| Dividend Yield | ★ 3.43% | N/A |
| EPS Growth | ★ 8.03 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $74.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.94 | $1.44 |
| 52 Week High | $29.71 | $4.75 |
| Indicator | ATLO | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | 47.61 |
| Support Level | $26.00 | $3.49 |
| Resistance Level | $29.71 | $4.10 |
| Average True Range (ATR) | 0.65 | 0.24 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 56.38 | 48.84 |
Ames National Corporation is a bank holding company based in the United States. Through its subsidiaries, it provides a range of banking and other financial products and services to customers in Iowa, mainly in Boone, Clarke, Hancock, Marshall, Polk, Story, Taylor, and Union in central, north-central, and south-central Iowa. The Group offers several financial products and services, including checking and savings accounts, time deposits, commercial, construction, and agricultural loans, personal loans, lines of credit, cash management services, merchant credit card processing, safe deposit boxes, and ATM services, among others. It caters to the banking needs of a diverse range of customers, including individuals, businesses, professionals, and enterprises.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.